NCT05163535 - Open Labelled, Randomized Study to Evaluate the Efficacy, Safety and Dose Selection of VM-1500A-LAI Drug in HIV-infected Patients Transferred From Previous Stable Therapy (NNRTI + 2NRTI), Including ELPIDA® | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 19, 2021

Primary Completion Date

August 3, 2021

Study Completion Date

August 3, 2021

Conditions

HIV-1-infection

Interventions

DRUG

VM-1500A-LAI

VM-1500A (parent drug of elsulfavirine) IM injection dosage form

OTHER

ELPIDA®

Elsulfavirine capsules

Trial Locations (2)

Federal State Budgetary Institution of the Central Research Institute of Epidemiology of Rospotrebnadzor, Moscow

"St. Petersburg State Medical Institution Center for AIDS and Infectious Diseases", Saint Petersburg